| Overview |
| bs-12378R-RBITC |
| UCMA Polyclonal Antibody, RBITC Conjugated |
| WB |
| Rat |
| Human, Mouse |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human UCMA |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 221044 |
| Secreted, Extracellular matrix |
| C10orf49; Gla rich protein; Gla-rich protein; Grp; GRP; OTTMUSP00000011599; RP23-272I15.1; UCMA; Ucma-C; UCMA_HUMAN; Unique cartilage matrix associated protein; Unique cartilage matrix-associated protein C-terminal fragment; Upper zone of growth plate and cartilage matrix associated. |
| UCMA is a 138 amino acid secreted protein that is highly expressed in resting chrondrocytes in developing long bones and is thought to function in the early phase of chrondrocyte differentiation. A furin-like protease processes UCMA into an N-terminal 37 amino acid peptide and a C-terminal 74 amino acid peptide, which is referred to as Unique cartilage matrix-associated protein C-terminal fragment (Ucma-C). Introduction of recombinant Ucma-C interferes with osteogenic differentiation of mesenchymal stem cells, MC3T3-E1 preosteoblasts and primary osteoblasts. This suggests that Ucma may be involved in the negative regulation of osteogenic differentiation of osteochondrogenic precursor cells at the cartilage-bone interface and in peripheral zones of fetal cartilage. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz